Melbourne, July 8, 2010 (ABN Newswire) - Melbourne’s Clinuvel Pharmaceuticals Limited (ASX:CUV) (PINK:CLVLY) today signed with a commercial US partner to manufacture its world’s first photoprotective drug, SCENESSE (R), under an exclusive arrangement. Following eight years of development, Clinuvel has selected Surmodics, Inc. (NASDAQ:SRDX), a leading Minnesota-based provider of proprietary drug delivery technologies to the healthcare industry, as its first manufacturing partner.
